Myomo, Inc. (MYO)
USD 4.88
(2.95%)
USD 4.88
(2.95%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -8.06 Million USD | 23.85% |
| 2022 | -10.12 Million USD | -1.99% |
| 2021 | -9.93 Million USD | 4.44% |
| 2020 | -11.23 Million USD | 4.59% |
| 2019 | -10.69 Million USD | -3.81% |
| 2018 | -10.45 Million USD | -679.57% |
| 2017 | -6.53 Million USD | 58.8% |
| 2016 | -3.26 Million USD | 7.4% |
| 2015 | -3.52 Million USD | -28.99% |
| 2014 | -2.73 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.8 Million USD | -64.59% |
| 2024 Q2 | -1.01 Million USD | 73.33% |
| 2023 FY | - USD | 23.85% |
| 2023 Q3 | -2.02 Million USD | -114.62% |
| 2023 Q1 | -2.5 Million USD | -12.29% |
| 2023 Q4 | -2.35 Million USD | -16.23% |
| 2023 Q2 | -943.22 Thousand USD | 62.32% |
| 2022 Q2 | -2.71 Million USD | -3.92% |
| 2022 Q1 | -2.61 Million USD | -0.93% |
| 2022 FY | - USD | -1.99% |
| 2022 Q4 | -2.22 Million USD | 16.25% |
| 2022 Q3 | -2.66 Million USD | 2.07% |
| 2021 Q4 | -2.59 Million USD | -34.03% |
| 2021 Q2 | -2.53 Million USD | 11.6% |
| 2021 Q1 | -2.87 Million USD | -70.17% |
| 2021 FY | - USD | 4.44% |
| 2021 Q3 | -1.93 Million USD | 23.79% |
| 2020 FY | - USD | 4.59% |
| 2020 Q2 | -2.82 Million USD | 16.91% |
| 2020 Q3 | -2.51 Million USD | 10.76% |
| 2020 Q4 | -1.68 Million USD | 33.03% |
| 2020 Q1 | -3.39 Million USD | -30.87% |
| 2019 Q4 | -2.59 Million USD | 7.79% |
| 2019 FY | - USD | -3.81% |
| 2019 Q3 | -2.81 Million USD | -1.14% |
| 2019 Q2 | -2.78 Million USD | -2.93% |
| 2019 Q1 | -2.7 Million USD | 1.35% |
| 2018 Q1 | -2.4 Million USD | -39.04% |
| 2018 Q4 | -2.74 Million USD | -1.41% |
| 2018 FY | - USD | -679.57% |
| 2018 Q2 | -2.67 Million USD | -11.1% |
| 2018 Q3 | -2.7 Million USD | -1.18% |
| 2017 Q2 | 3.37 Million USD | 352.2% |
| 2017 Q1 | -1.33 Million USD | -22.06% |
| 2017 Q3 | -1.65 Million USD | -149.07% |
| 2017 Q4 | -1.72 Million USD | -4.5% |
| 2017 FY | - USD | 58.8% |
| 2016 Q4 | -1.09 Million USD | -17.51% |
| 2016 Q2 | -688.57 Thousand USD | -23.82% |
| 2016 Q3 | -931.95 Thousand USD | -35.35% |
| 2016 Q1 | -556.09 Thousand USD | 34.38% |
| 2016 FY | - USD | 7.4% |
| 2015 FY | - USD | -28.99% |
| 2015 Q1 | -916.63 Thousand USD | 0.0% |
| 2015 Q4 | -847.46 Thousand USD | 0.0% |
| 2015 Q3 | -847.46 Thousand USD | 7.55% |
| 2015 Q2 | -916.63 Thousand USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 100.077% |
| Allurion Technologies Inc. | -69.03 Million USD | 88.314% |
| Artivion, Inc. | 38.14 Million USD | 121.151% |
| Avanos Medical, Inc. | 53.2 Million USD | 115.164% |
| Butterfly Network, Inc. | -124.84 Million USD | 93.538% |
| Butterfly Network, Inc. | -124.84 Million USD | 93.538% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 98.674% |
| Boston Scientific Corporation | 3.45 Billion USD | 100.234% |
| CONMED Corporation | 182.18 Million USD | 104.428% |
| Edwards Lifesciences Corporation | 1.76 Billion USD | 100.456% |
| Paragon 28, Inc. | -36.61 Million USD | 77.967% |
| Glaukos Corporation | -82.11 Million USD | 90.176% |
| Globus Medical, Inc. | 418.23 Million USD | 101.929% |
| Inspire Medical Systems, Inc. | -17.06 Million USD | 52.713% |
| Integer Holdings Corporation | 282.05 Million USD | 102.86% |
| Medtronic plc | 9.05 Billion USD | 100.089% |
| Nevro Corp. | -78.31 Million USD | 89.698% |
| Owlet, Inc. | -27.48 Million USD | 70.653% |
| Penumbra, Inc. | 111.99 Million USD | 107.203% |
| Vicarious Surgical Inc. | -69.19 Million USD | 88.341% |
| Smith & Nephew plc | 979 Million USD | 100.824% |
| STERIS plc | 1.41 Billion USD | 100.571% |
| Stryker Corporation | 5.16 Billion USD | 100.156% |
| Vapotherm, Inc. | -34.35 Million USD | 76.519% |
| Zimmer Biomet Holdings, Inc. | 2.44 Billion USD | 100.329% |